Minoryx Phase 2/3 ‘ADVANCE’ study results to be presented at the 2021 American Neurological Association (AAN) Annual Meeting Additional clinical data will show benefits of leriglitazone in adrenomyeloneuropathy (... 12/04/2021
Minoryx presents topline results from Phase 2/3 “ADVANCE” study demonstrating significant clinical benefit of leriglitazone in adrenomyeloneuropathy (AMN) Largest prospective efficacy study conducted in the orphan disease AMN ... 26/01/2021
Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich´s ataxia Study demonstrates leriglitazone improves relevant disease biomarkers and ataxia resulting ... 15/12/2020
Headquarters https://www.minoryx.com/content/imgs/mail/logo.png Av. Ernest Lluch 32 - TCM3 08302 Mataró (Barcelona) Spain
Belgian R&D Site https://www.minoryx.com/content/imgs/mail/logo.png Rue Auguste Piccard 48, I - Tech Incubator 6041 Gosselies (Charleroi) Belgium